# Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim

> **NCT01489423** · — · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 270 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **GENETIC:** RNA analysis
- **GENETIC:** in situ hybridization
- **GENETIC:** polymerase chain reaction
- **OTHER:** enzyme-linked immunosorbent assay
- **OTHER:** flow cytometry
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01489423
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-26
- **Primary completion:** 2013-05-26
- **Final completion:** 2013-05-26
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2017-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01489423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01489423, "Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01489423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*